REGENERON PHARMACEUTICALS, INC. Unrecognized Tax Benefits, Period Increase (Decrease)
REGENERON PHARMACEUTICALS, INC. (REGN) reported Unrecognized Tax Benefits, Period Increase (Decrease) of $5.60 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-07.
Discontinued › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease · last filed 2019-02-07
- REGENERON PHARMACEUTICALS, INC. unrecognized tax benefits, period increase (decrease) for fiscal 2018 was $5.60M.
- REGENERON PHARMACEUTICALS, INC. unrecognized tax benefits, period increase (decrease) for fiscal 2017 was -$5.60M.
- REGENERON PHARMACEUTICALS, INC. unrecognized tax benefits, period increase (decrease) for fiscal 2016 was -$42.30M.
- REGENERON PHARMACEUTICALS, INC. unrecognized tax benefits, period increase (decrease) for fiscal 2015 was -$952.00K, a 114.73% decline from fiscal 2014.
| Period end | Unrecognized Tax Benefits, Period Increase (Decrease) 12 month | Unrecognized Tax Benefits, Period Increase (Decrease) 12 month as first filed |
|---|---|---|
| 2018-12-31 | $5.60M 10-K · filed 2019-02-07 | |
| 2017-12-31 | -$5.60M 10-K · filed 2019-02-07 | -$5.61M 10-K · filed 2018-02-08 |
| 2016-12-31 | -$42.30M 10-K · filed 2019-02-07 | -$42.28M 10-K · filed 2017-02-09 |
| 2015-12-31 | -$952.00K 10-K · filed 2018-02-08 | |
| 2014-12-31 | $6.46M 10-K · filed 2017-02-09 | |
| 2013-12-31 | $8.30M 10-K · filed 2016-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |